Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
01 Febrero 2024 - 6:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced it will highlight new
technology innovations and three-year interim ALIGN3D™ clinical
results at the 2024 American College of Foot and Ankle Surgeons
(“ACFAS”) Annual Scientific Conference in Tampa, Florida from
February 1-4, 2024.
“Our continued strong presence at ACFAS
underscores Treace's longstanding commitment to investing in the
field of foot and ankle surgery,” said John T. Treace, CEO, Founder
and Board Member of Treace. “During this year’s ACFAS conference,
we are excited to highlight several new innovations from our robust
pipeline of ten focused product launches slated from the second
half of 2023 through 2024. We also look forward to sharing
compelling three-year data from our ALIGN3D™ study in a podium
presentation at ACFAS this Friday.”
Treace will feature its current and
next-generation technologies at its ACFAS exhibit booth and host
Lapiplasty® and Adductoplasty® surgeon training events featuring
recent innovations, including:
-
Expanded SpeedPlate™ Configurations: Innovative
fixation technology designed to deliver the stability of a titanium
locking plate with the speed of insertion and compression of a
staple. While broadly applicable across Lapiplasty® and
Adductoplasty® procedures today, new SpeedPlate™ implant
configurations are designed to expand the versatility of the
SpeedPlate™ platform to address a wide range of additional fusion
procedures throughout the foot. These new SpeedPlate™
configurations are expected to be available in the first half of
2024.
-
Micro-Lapiplasty™ System:
Proprietary, advanced instrumentation designed to enable the
patented Lapiplasty® Procedure to be performed through a
minimally-invasive 2cm incision utilizing new SpeedPlate™ implant
technology for fixation. The Micro-Lapiplasty™ System is now in
full commercial release and will be featured in hands-on training
workshops at the conference.
-
Mini-Adductoplasty™ System: New, advanced
instrumentation designed to allow the Adductoplasty® Midfoot
Deformity Correction procedure to be performed through a ~50%
smaller incision and leverages SpeedPlate™ implant technology for
fixation. The Mini-Adductoplasty™ System is currently in limited
clinical release with full commercialization planned in the second
half of 2024.
-
RedPoint™ Patient-Specific Instrumentation (PSI):
First-to-market technology designed to deliver pre-operative
planning and patient-specific guides for surgical correction of
foot deformities. RedPoint™ PSI is currently in limited clinical
release with full commercialization planned in the second half of
2024.
-
Recently introduced Hammertoe PEEK Fixation System
and the LapiTome™ and RazorTome™
single-use osteotomes will also be featured at the conference.
More information on Treace’s products can be
found at www.lapiplasty.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements, including, but not
limited to, the planned full commercialization of the Company’s
Mini-Adductoplasty™ System and RedPoint™ Patient Specific
Instrumentation in the second half of 2024. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Factors that could cause actual results
or other events to differ materially from those contemplated in
this press release can be found in the Risk Factors section of
Treace’s public filings with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended
December 31, 2022, and its subsequent SEC filings. Because
forward-looking statements are inherently subject to risks and
uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of their date and, except to the extent
required by law, the Company undertakes no obligation to update
these statements, whether as a result of any new information,
future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion
Correction® system – a combination of instruments, implants,
and surgical methods designed to surgically correct all 3 planes of
the bunion deformity and secure the unstable joint, addressing the
root cause of the bunion and helping patients get back to their
active lifestyles. To further support the needs of bunion patients,
Treace has introduced its Adductoplasty® Midfoot Correction
System, designed for reproducible surgical correction of the
midfoot as well as its Hammertoe PEEK Fixation System designed to
address hammertoe, claw toe and mallet toe deformities. The company
continues to expand its footprint in the foot and ankle market with
the introduction of its SpeedPlate™ Rapid Compression
Implants, an innovative fixation platform with broad versatility
across Lapiplasty® and Adductoplasty® procedures, as well
as other common bone fusion procedures of the foot. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical Concepts,
Inc.Julie Dewey, IRCChief Communications & Investor
Relations Officerjddewey@treace.com | 209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De May 2023 a May 2024